GSK Stock Recent News

Sarat Sethi, managing partner and portfolio manager at DCLA, joins CNBC's 'Squawk Box' to break down potential market strategies and stocks to watch ahead of the open. Sethi also breaks down how he's navigating markets amid uncertainty around China and its zero-Covid strategy.

GSK PLC GSK, +0.87% said Tuesday that it has started the withdrawal process of the U.S. marketing authorization for its Blenrep treatment, following the request of the country's Food and Drug Administration.

GSK PLC (LSE:GSK, NYSE:GSK) has started for withdrawal process for US marketing authorisation for Blenrep following a request of the US Food and Drug Administration (FDA).  The request followed the previously announced outcome of the DREAMM-3 phase III trial which failed to meet FDA requirements wiping around £1.7bn of the FTSE 100 listed group's share price.

GSK plc (NYSE:GSK ) 13th Annual Jefferies London Healthcare Conference 2022 November 16, 2022 4:45 AM ET Company Participants David Redfern - Chief Strategy Officer Conference Call Participants Peter Welford - Jefferies Peter Welford Thank you all very much. We've got a bit of room around the front that's why - over the head if people want to move around.

Shares of GSK GSK, -3.85% fell nearly 4% in London as UBS downgraded the pharmaceutical giant to sell from neutral. “We see two factors posing risks to the earnings base longer term – blockbuster vaccine Shingrix will exhaust its catch-up patient pool in the U.S. around '27 and HIV product dolutegravir faces patent expiry at the same time.

GSK PLC (LSE:GSK, NYSE:GSK) shares have been slapped with a 'sell' rating by UBS, which downgraded its recommendation as it sees two big long-term risks ahead.  Admittedly, the risks are all the way out in 2027, when the Swiss bank worries that blockbuster shingles vaccine Shingrix will "exhaust its catch-up patient pool in the US" and HIV product dolutegravir faces patent expiry.

British pharmaceutical company GSK has seen an 8% price rise since I wrote about it a little over a month ago. What has driven this? Its upgraded earnings outlook and approvals for its treatments have likely buoyed the stock, adding to the already improving market mood.

GSK PLC (LSE:GSK, NYSE:GSK) said the second-line applications of its cancer drug will be limited in scope. The front-line use of Zejula, which has been developed to treat epithelial ovarian, fallopian tube, or primary peritoneal cancers, remains unchanged.

By Michael Susin

City broker Shore Capital remained upbeat on the prospects for shares in GSK PLC (LSE:GSK, NYSE:GSK) in spite of the failure of a key clinical trial for a new bone marrow cancer drug. It repeated its ‘buy' recommendation and said stock in the pharma giant was materially undervalued compared with its peers.